01Principles and purposeThe professional or clinical skill and the decisions it supports.
Planning medicines management asks what should happen next for this person, not simply what drug treats the diagnostic label. The best option may be to introduce treatment, correct how it is used, simplify an existing regimen or pause while an acute problem is assessed. Several conditions may compete for attention, and the person’s priorities may not match the order in which they appear in the record. Someone worried about falling at home may value alertness and mobility more immediately than a small improvement in an asymptomatic laboratory target. That preference does not erase preventive benefit, but it changes how trade-offs should be discussed and sequenced.
A coherent plan links each action to an expected outcome and a way to assess it. If a sedating medicine is stopped because its original indication has resolved, the review should ask whether alertness improves and whether the original symptom returns. If an antihypertensive is reduced because of postural symptoms, pressure and function both matter. If a new protective medicine is added, the team should anticipate its monitoring and practical burden before issuing it. This approach avoids a chain of disconnected prescriptions in which each new symptom produces another tablet while the cumulative regimen becomes increasingly difficult to tolerate or administer.
Key points
- Begin with the problem and the desired outcome, then choose among starting, continuing, changing, reducing or stopping treatment. A management plan is broader than naming another medicine.
- Identify immediate instability before routine optimisation. Hypotension with poor perfusion, dangerous electrolytes or a suspected serious adverse reaction needs acute assessment.
- Reconstruct the reason for every medicine and ask whether it remains current. Short-term symptom treatment can persist long after the symptom has resolved.
- Consider benefit, harm, treatment burden, time to benefit and the person’s priorities together, particularly with frailty or multimorbidity.
- Deprescribing should be planned: identify what stops, whether tapering is needed, how symptoms will be observed and when the decision will be reviewed.
- Benzodiazepines, Z-drugs, opioids and antidepressants can cause withdrawal. Unless exceptional clinical risk requires rapid action, use an individual slow reduction plan rather than abrupt routine cessation.
- Assign responsibility for prescriptions, supply, monitoring and follow-up. The patient should know the next action and whom to contact if the plan does not work.
02Situations and prioritiesThe context, relevant information and actions that matter most.
Ask what matters most now: symptom relief, independence, avoiding hospital, preventing future events or reducing the number of daily tasks. Explore what the person believes each medicine does and which effects trouble them. A clear preference can guide sequencing without assuming that the patient wants all preventive therapy stopped.
For each medicine, establish indication, start date, benefit and intended duration. A short course may remain on a repeat list because no one completed the stop decision. Conversely, an apparently asymptomatic condition may still justify treatment that prevents a serious future event. Recover the rationale before deciding that lack of current symptoms means lack of benefit.
Consider tablet count, administration times, monitoring visits, swallowing, device use and carer support. A regimen may be technically appropriate yet unmanageable. Ask about actual routines and supply problems, because simplifying frequency or improving access may achieve more than changing the pharmacological class.
Determine whether abrupt cessation could produce withdrawal, physiological rebound or loss of disease control. Long-term benzodiazepines and other dependence-associated medicines need a different stopping plan from a brief unnecessary antihistamine course. Explain that a gradual reduction is a safety strategy and can be adjusted in response to symptoms.
03Assessment and interpretationHow to gather information, assess the situation and recognise uncertainty.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Structured medication history with indications - Why
- Build the factual basis for an integrated management plan.
- Interpretation and limitations
- Combine the patient’s account with available prescribing and specialist records. Document uncertainty when a medicine’s purpose cannot yet be established. Do not substitute assumptions about common uses for the actual indication, particularly with drugs that can treat several unrelated conditions.
- 02
Functional and adverse-effect assessment - Why
- Measure the outcomes most relevant to the person’s current concern.
- Interpretation and limitations
- Falls, daytime alertness, pain interference, sleep, mobility and daily activities can be more useful review measures than a generic symptom question. Establish a baseline so that a trial change has something to be compared with. Consider competing diagnoses rather than attributing all impairment to medicines.
- 03
Targeted observations and laboratory tests - Why
- Identify safety constraints that alter the order of management actions.
- Interpretation and limitations
- Choose tests that address the proposed decision: standing pressure for postural symptoms, renal function for accumulating medicines, or relevant electrolytes for an arrhythmia risk. Testing every possible parameter can increase burden without resolving the actual uncertainty.
- 04
Current evidence and individual risk context - Why
- Estimate likely benefit and harm of continuation or change.
- Interpretation and limitations
- Apply guidance to the patient group it describes, then consider frailty, comorbidity, preferences and feasibility. A population recommendation should inform the discussion rather than determine it mechanically. When evidence is limited for a complex situation, document the uncertainty and seek appropriate advice.
04Worked approachesCases with ordered reasoning, an action and a check of the outcome.
01Worked exampleRemove a resolved indication from a burdensome regimenA 78-year-old with two recent non-injurious falls reports new daytime drowsiness. Hydroxyzine 25 mg orally nightly began 3 weeks ago for itch that has resolved. Other medicines are unchanged. Seated pressure is 132/74 mmHg, standing pressure 128/72, pulse 72 regular, and there are no syncope, focal neurological or acute illness features.+
- 1Assess the falls and supplied observations, checking injury, gait and other causes rather than assuming medicine causation. The stable standing pressure does not support reflex reduction of every antihypertensive, while the new sedating medicine has a clear temporal relationship to drowsiness.
- 2Reconstruct the hydroxyzine indication: the itch has resolved, so ongoing benefit is uncertain. Its sedating and anticholinergic burden is relevant in this older adult, and MHRA advises avoiding use in older people where possible because susceptibility to adverse effects is greater.
- 3Agree the final medicine action to stop the unnecessary hydroxyzine, with appropriate non-drug skin care and reassessment if itch returns, while preserving other treatment pending its own review. Explain the expected improvement in alertness and the need to report another fall or new warning symptoms.
- 4Arrange contact within several days and a fuller review within 1–2 weeks for this illustrative plan. Independently verify that the repeat list and supplied tablets no longer direct nightly use, ask the patient to repeat the change, and compare alertness, falls and itch with the baseline at follow-up.
02PrioritisationBuild a plan for several competing medicine problemsA patient with multimorbidity has adverse effects, uncontrolled symptoms and a complex regimen.+
- 1Identify any immediate safety threat and stabilise it before routine optimisation. Then agree the most important patient-centred outcome and make a short list of medicine changes likely to address it, rather than altering every condition in one encounter.
- 2For each proposed action, compare expected benefit, harm and burden with the alternatives, including improved administration or a non-drug intervention. Check whether stopping one medicine changes the dose or need for another through an interaction or loss of a protective effect.
- 3Choose a manageable sequence with clear starting, stopping or titration instructions. Where several changes are necessary together, specify the monitoring that will help distinguish their effects and assign a clinician to coordinate the overall plan.
- 4Document what remains unchanged for an active reason, what needs further information and when the whole plan will be reviewed. Confirm supply and support so that the agreed treatment is feasible between appointments.
03Withdrawal planningReduce a dependence-associated medicine safelyAn adult taking a long-term benzodiazepine wants to stop because of adverse effects.+
- 1Clarify dose, duration, actual use, previous withdrawal attempts and the condition being treated. Assess urgent risks and discuss the potential benefits of reduction alongside the possibility of withdrawal symptoms or return of the original problem.
- 2Agree an individual gradual reduction consistent with current NICE guidance, usually with smaller decrements as the dose becomes lower. Avoid imposing a rigid schedule that cannot respond to symptoms, and confirm that the required strengths or formulations can be supplied accurately.
- 3Provide the written dose plan, review dates and advice on whom to contact if symptoms become troublesome. Distinguish expected adaptation from features needing urgent assessment, and avoid adding another dependence-associated medicine automatically to treat withdrawal discomfort.
- 4At each review, assess symptoms, functioning and the person’s preference before the next step. Adjust the pace or pause when appropriate, documenting the next agreed action so that a temporary pause is not mistaken for abandonment of the entire plan.
05Feedback, follow-up and evidenceReview outcomes, seek feedback and identify what to improve.
- Use the outcome that justified the change to judge its effect. After reducing sedative burden, ask about alertness, falls and participation in daily activities; a shorter medication list alone does not prove that the patient is better.
- Check for return of the treated condition and for withdrawal where relevant. A recurrence may need re-evaluation or a different approach, while withdrawal may indicate that the reduction should be slowed rather than that lifelong treatment is inevitable.
- Review the practical implementation: can the patient obtain the new strength, distinguish old supplies and follow the schedule? A carefully negotiated plan may fail because the pharmacy continues an automatic repeat of the previous dose.
- Coordinate changes across specialists and primary care, especially when one medicine has several indications. Make the reasoning visible so that a subsequent clinician does not restart a deliberately stopped medicine without understanding the previous benefit–harm assessment.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Deprescribing is a therapeutic trial
Stopping a medicine can be approached with the same discipline as starting one: a hypothesis, an agreed action, outcomes to observe and a review point. This makes the decision revisable without treating every recurrence as evidence that the original review was wrong.
Time to benefit matters
Immediate treatment burden and a preventive benefit expected over years should be discussed in the context of the person’s goals and health trajectory. Avoid assuming that either short-term comfort or long-term prevention always dominates the decision.
One clear change can reveal causality
When clinically reasonable, a focused change can show whether a suspected adverse effect improves. Multiple simultaneous changes may be necessary for safety, but they make it harder to identify which medicine caused the original problem.
A plan has operational components
The clinical choice, prescription, supply, patient understanding and review responsibility all contribute to the outcome. Failure in any one component can make an otherwise sensible medicine strategy ineffective or unsafe. Ask the person to bring or show their current supplies when several strengths remain at home. Distinguishing which packets to retain and which to return can prevent an agreed reduction from being undone by an older label.
07Common pitfallsFrequent interpretation and management errors.
- 01
Adding a medicine for a suspected adverse effect without reviewing the original drug can create an avoidable prescribing cascade.
- 02
Assuming that all long-term medicines can be stopped in the same way overlooks withdrawal, rebound and the loss of essential disease control.
- 03
Using age alone to discontinue preventive treatment can miss meaningful benefit and bypass the person’s own priorities.
- 04
Agreeing a taper that cannot be delivered with available formulations leaves the patient to improvise doses and undermines the planned reduction.